So What Really Is New in the Pharmacotherapy of Attention-Deficit/Hyperactivity Disorder?

Child Adolesc Psychiatr Clin N Am. 2022 Jul;31(3):xiii-xiv. doi: 10.1016/j.chc.2022.03.011. Epub 2022 May 11.

Authors

Jeffrey H Newcorn¹, Timothy E Wilens²

Affiliations

¹ Division of ADHD and Learning Disorders, Icahn School of Medicine at Mount Sinai, Pediatric Psychopharmacology, Mount Sinai Health System, New York, NY 10029, USA. Electronic address: jeffrey.newcorn@mssm.edu.
² Division of Child and Adolescent Psychiatry, Center for Addiction Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA. Electronic address: TWILENS@mgh.harvard.edu.

PMID: 35697403
DOI: 10.1016/j.chc.2022.03.011

No abstract available

Publication types

Editorial

MeSH terms

Attention Deficit Disorder with Hyperactivity* / drug therapy
Central Nervous System Stimulants* / therapeutic use
Humans

Substances

Central Nervous System Stimulants